Interestingly, CAR-T cells expanded with IL-15 exhibited a higher anticancer efficacy as compared to IL-2-supplemented CD19 CAR-T cells against a lymphoma cell line in vivo [58]. This evidence concerns the gene CD19 and lymphoma.